Zoetis Inc. (NYSE:ZTS) is a prominent player in the animal health industry, providing a wide range of products and services for pets and livestock. The company is known for its innovative solutions in parasiticides, diagnostics, and dermatology. Zoetis faces competition from other major firms in the sector, but it continues to maintain a strong market presence.
On November 4, 2025, Stifel Nicolaus set a price target of $140 for Zoetis, suggesting a potential upside of about 11.56% from its trading price of approximately $125.50 at the time. This optimistic outlook is supported by Zoetis's strong financial performance in the third quarter of 2025. The company reported an adjusted earnings per share of $1.70, surpassing the consensus estimate of $1.62.
Zoetis's adjusted net income reached $754 million, reflecting a 5% increase on a reported basis and a 9% rise on an organic operational basis. The company's sales amounted to $2.4 billion, a 1% year-over-year increase, although slightly below the expected $2.41 billion. This growth was driven by the success of its parasiticides, diagnostics, and dermatology portfolios.
However, Zoetis faced challenges with its monoclonal antibody products for osteoarthritis pain, such as Librela for dogs and Solensia for cats, which experienced a decline. Additionally, sales of livestock products fell by 9% due to the divestiture of the medicated feed additive product portfolio. Despite these challenges, Zoetis remains focused on its strategic priorities.
The stock for ZTS is currently priced at $126.06, reflecting a decrease of approximately 12.67% from its previous high. The stock has fluctuated between a low of $122.03 and a high of $128.11 today. Zoetis's market capitalization stands at approximately $55.87 billion, with a trading volume of 7,642,200 shares. The company continues to adapt to macroeconomic trends and the operational environment.
